Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cordis Corporation
Cypher stent featured in more than 25 studies at the AHA meeting
December 7th, 2004
Clinical data regarding the use of the Cypher Sirolimus-eluting Coronary Stent in treating challenging coronary lesions in a variety of patient populations were presented at the 2004 American Heart Association Scientific Sessions in New Orleans, Louisiana. The Cypher Stent remains the most studied drug-eluting stent available today. Among the more than 25 key Cypher Stent presentations at the international medical conference are results from the robust, international e-Cypher registry, which tracks use of the device in more than 15,000 patients; and studies that evaluate the Cypher Stent's performance in complex cases, including diabetic patients,...
Source: Cardiovascular Business Week (2004-12-07)
|
